DiscoverASTCT TalksDelayed Neurotoxicity With Car-T Therapy in Myeloma: What Clinicians Need To Know
Delayed Neurotoxicity With Car-T Therapy in Myeloma: What Clinicians Need To Know

Delayed Neurotoxicity With Car-T Therapy in Myeloma: What Clinicians Need To Know

Update: 2025-07-17
Share

Description

In this episode of ASTCT Talks, Dr. Rahul Banerjee sits down with Dr. Kenneth Lim and Dr. Yi Lin of Mayo Clinic to discuss a critical and emerging topic in CAR T-cell therapy: delayed neurotoxicities following cilta-cel treatment in multiple myeloma. They break down the clinical features of nerve palsies and Parkinsonism-like symptoms, share diagnostic and treatment strategies and explore emerging predictive markers like absolute lymphocyte count. Given that cilta-cel is increasingly being used in second-line myeloma treatment and is even being studied in first-line treatment to replace stem cell transplantation, this conversation is a timely and insightful look at improving patient outcomes in CAR T-cell therapy.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Delayed Neurotoxicity With Car-T Therapy in Myeloma: What Clinicians Need To Know

Delayed Neurotoxicity With Car-T Therapy in Myeloma: What Clinicians Need To Know

ASTCT